CVRx, Inc. Reports Strong Q2 2025 Growth

Cvrx, Inc. ( (CVRX) ) has released its Q2 earnings. Here is a breakdown of the information Cvrx, Inc. presented to its investors.

CVRx, Inc. is a commercial-stage medical device company specializing in innovative neuromodulation solutions for cardiovascular diseases, notably through its Barostim technology. In its second quarter of 2025, CVRx reported a revenue increase of 15% year-over-year, reaching $13.6 million. The U.S. heart failure segment contributed significantly to this growth, with revenue climbing to $12.1 million. The company also expanded its active implanting centers in the U.S. to 240, a 27% increase from the previous year, highlighting its strategic growth in new sales territories and increased awareness of Barostim.

Key financial metrics for the quarter included a gross profit of $11.5 million, maintaining an 84% gross margin, and a net loss of $14.7 million, slightly higher than the previous year. The company’s operating expenses rose due to increased compensation and travel costs, while R&D expenses saw a reduction. Additionally, CVRx announced the appointment of Brent Binkowski as Chief Operating Officer, aiming to bolster its operational and strategic capabilities.

Looking ahead, CVRx has narrowed its full-year revenue guidance to between $55.0 million and $57.0 million, with expectations of continued growth driven by its expanding commercial footprint and favorable reimbursement conditions. The company remains optimistic about its strategic initiatives and market position, anticipating further advancements in its clinical evidence strategy and reimbursement landscape.